I Craig Henderson

Summary

Publications

  1. ncbi request reprint Can we abandon anthracyclines for early breast cancer patients?
    I Craig Henderson
    Department of Medicine, University of California at San Francisco, USA
    Oncology (Williston Park) 25:115-24, 127. 2011
  2. ncbi request reprint Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer
    Beth Overmoyer
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106 5055, USA
    Clin Breast Cancer 6:150-7. 2005
  3. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
  4. ncbi request reprint Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole
    Robert W Carlson
    Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
    Breast Cancer Res Treat 80:S19-26; discussion S27-8. 2003

Detail Information

Publications4

  1. ncbi request reprint Can we abandon anthracyclines for early breast cancer patients?
    I Craig Henderson
    Department of Medicine, University of California at San Francisco, USA
    Oncology (Williston Park) 25:115-24, 127. 2011
    ..The results of these studies are provocative but insufficient to justify the conclusion that anthracyclines can be either abandoned or used only for a very select group of patients...
  2. ncbi request reprint Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer
    Beth Overmoyer
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106 5055, USA
    Clin Breast Cancer 6:150-7. 2005
    ..Pegylated liposomal doxorubicin (PLD) is an active agent for breast cancer. The efficacy and safety of PLD in combination with cyclophosphamide as first-line treatment of metastatic breast cancer (MBC) was evaluated in this phase II study...
  3. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
  4. ncbi request reprint Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole
    Robert W Carlson
    Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
    Breast Cancer Res Treat 80:S19-26; discussion S27-8. 2003
    ....